Patent intelligence · US
US 9873964
Dispersible non-woven fabrics
Dispersible non-woven fabrics
Patent details — US 9873964
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 23, 2018
- Expiration
- Jan 18, 2038
- Applicant
- LENZING AKTIENGESELLSCHAFT
- Claims
- 32
- CPC classes
- A61K, A61K2800/10, A61K8/0208, A61K8/731
Quick answer
US 9873964 (Dispersible non-woven fabrics) is held by LENZING AKTIENGESELLSCHAFT. Status: granted. Granted Jan 23, 2018. Expires Jan 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LENZING AKTIENGESELLSCHAFT
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K2800/10, A61K8/0208, A61K8/731
More from LENZING AKTIENGESELLSCHAFT
Related pharmaceutical patents in our USPTO index.
-
US 12414942
Compositions, methods, and systems for treating presbyopia
granted -
US 12180206
Aceclidine derivatives, compositions thereof and methods of use thereof
granted -
US 12128036
Compositions and methods for storage stable ophthalmic drugs
granted -
US 11648247
Compositions and methods for the treatment of presbyopia
granted -
US 11344538
Methods for the treatment of myopia
granted -
US 11273150
Compositions and methods for the treatment of presbyopia
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11179328
Compositions and methods for the treatment of presbyopia
granted
Frequently asked questions
What is US patent 9873964?
US 9873964 (Dispersible non-woven fabrics) is held by LENZING AKTIENGESELLSCHAFT. Status: granted. Granted Jan 23, 2018. Expires Jan 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9873964?
LENZING AKTIENGESELLSCHAFT is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 9873964 expire?
Our index shows an expiration date of Jan 18, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.